The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses: an individual participant meta-analysis by Voysey, M, Kelly, D, Fanshawe, T, Sadarangani, M, O'Brien, K, Perera, R, Pollard, A

“…Importance: The design of infant immunization schedules requires an understanding of the factors that determine the immune response to each vaccine antigen. …”

Antenatal magnesium sulphate to prevent cerebral palsy in very preterm infants. by Doyle, L, Crowther, C, Middleton, P, Voysey, M, Marret, S, Rouse, D

Maternal antibody interference, immunisation schedules, and protective antibody levels in infants by Voysey, M

“…</p> <p>In this thesis I explore the waning of maternal transplacental antibody, its effect on the immunogenicity of infant vaccines, and the timing and spacing of infant doses. …”

Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. by Askie, L, Ballard, R, Cutter, G, Dani, C, Elbourne, D, Field, D, Hascoet, J, Hibbs, A, Kinsella, J, Mercier, J, Rich, W, Schreiber, MD, Wongsiridej, P, Subhedar, N, Meurs, V, Voysey, M, Barrington, K, Ehrenkranz, R, Finer, N

“… BACKGROUND: Inhaled nitric oxide (iNO) is an effective therapy for pulmonary hypertension and hypoxic respiratory failure in term infants. Fourteen randomized controlled trials (n = 3430 infants) have been conducted on preterm infants at risk for chronic lung disease (CLD). …”

Seroepidemiology of SARS-CoV-2 in a cohort of pregnant women and their infants in Uganda and Malawi by Hookham, L, Cantrell, L, Cose, S, Freyne, B, Gadama, L, Imede, E, Kawaza, K, Lissauer, S, Musoke, P, Nankabirwa, V, Sekikubo, M, Sommerfelt, H, Voysey, M, Le Doare, K

“…<p><strong> Results</p></strong> In total, 1379 women were enrolled, giving birth to 1387 infants. Overall, 63% of pregnant women had a SARS-CoV-2 positive serology. …”

Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule by Trück, J, Mitchell, R, Jawad, S, Clutterbuck, E, Snape, M, Kelly, D, Voysey, M, Pollard, A

Inhaled Nitric Oxide in preterm infants: a systematic review and individual patient data meta-analysis by Askie, L, Ballard, R, Cutter, G, Dani, C, Elbourne, D, Field, D, Hascoet, J, Hibbs, A, Kinsella, J, Mercier, J, Rich, W, Schreiber, MD, Srisuparp, P, Subhedar, N, Meurs, V, Voysey, M, Barrington, K, Ehrenkranz, R, Finer, N

“…Inhaled Nitric Oxide, an effective therapy for pulmonary hypertension and hypoxic respiratory failure in the full term infant, has also been studied in preterm infants. …”

The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis by Oguti, B, Ali, A, Andrews, N, Barug, D, Anh Dang, D, Halperin, SA, Thu Hoang, HT, Holder, B, Kampmann, B, Kazi, AM, Langley, JM, Leuridan, E, Madavan, N, Maertens, K, Maldonado, H, Miller, E, Munoz-Rivas, FM, Omer, SB, Pollard, AJ, Rice, TF, Rots, N, Sundaram, ME, Wanlapakorn, N, Voysey, M

“…Blood samples were taken at two timepoints before any DTP-containing vaccines were received by the infant: at birth and at 2-months of age. Decay rates for each antigen were log2-transformed and a mixed effects model was applied. …”

Sex-dependent immune responses to infant vaccination: An individual participant data meta-analysis of antibody and memory B cells by Voysey, M, Barker, C, Snape, M, Kelly, D, Trück, J, Pollard, A

Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom by Kandasamy, R, Voysey, M, Collins, S, Berbers, G, Robinson, H, Noel, I, Hughes, H, Ndimah, S, Gould, K, Fry, N, Sheppard, C, Ladhani, S, Snape, M, Hinds, J, Pollard, A

Pneumococcal serotype-specific antibodies persist through early childhood after infant immunization: follow-up from a randomized controlled trial by Trück, J, Snape, MD, Tatangeli, F, Voysey, M, Yu, L, Faust, SN, Heath, P, Finn, A, Pollard, A

“…Persistence of immunity following infant immunization with either PCV-7 or PCV-13 and the immune response to a PCV-13 booster at pre-school age were investigated. …”

Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) — a protocol for two parallel, open-label, randomised controlled trials by Kelly, S, Liu, X, Theiss-Nyland, K, Voysey, M, Murphy, S, Li, G, Nyantaro, M, Gurung, M, Basnet, S, Pokhrel, B, Bijukchhe, SM, Eordogh, A, Gombe, B, Kakande, A, Kerridge, S, Kimbugwe, G, Kusemererwa, S, Lubyayi, L, Luzze, H, Mazur, O, Mujadidi, YF, Nabukenya, S, Nagumo, W-R, Nareeba, T, Noristani, R, O'Reilly, P, Roberts, A, Shah, G, Shrestha, S, Shrestha, LP, Thapa, SB, Kibengo, FM, Sharma, AK, Elliott, A, Shrestha, S, Pollard, AJ

“…New vaccines for other diseases continue to be introduced into the infant immunisation schedule, resulting in an increasingly crowded schedule. …”

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. by Pace, D, Khatami, A, McKenna, J, Campbell, D, Attard-Montalto, S, Birks, J, Voysey, M, White, C, Finn, A, Macloed, E, Faust, S, Kent, A, Heath, P, Borrow, R, Snape, M, Pollard, A

“…PARTICIPANTS: Healthy infants aged 6-12 weeks followed up until age 24 months. …”

Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age by Snape, M, Pollard, A, Voysey, M, Finn, A, Bona, G, Esposito, S, Principi, N, Diez-Domingo, J, Sokal, E, Kieninger, D, Prymula, R, Dull, P, Kohl, I, Barone, M, Wang, H, Toneatto, D

“…<strong>Background:</strong> A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. …”

The impact of administration of conjugate vaccines containing cross reacting material on Haemophilus influenzae type b antibody responses in infants: A systematic review and meta-analysis of randomised controlled trials by Voysey, M, Sadarangani, M, Clutterbuck, E, Bolgiano, B, Pollard, A

“…CRM conjugate vaccines have been reported to suppress antibody responses to co-administered Hib-TT vaccine.We conducted a systematic review and meta-analysis of randomised controlled trials in which infants were randomised to receive meningococcal or pneumococcal conjugate vaccines along with Hib-TT. …”

Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial. by Iro, M, Khatami, A, Marshall, A, Pace, D, Voysey, M, McKenna, J, Campbell, D, Attard-Montalto, S, Finn, A, White, C, Faust, SN, Kent, A, Heath, P, MacLeod, E, Stanford, E, Findlow, H, Almond, R, Bai, X, Borrow, R, Snape, MD, Pollard, A

“…We aimed to assess whether this phenomenon also occurs with routine infant vaccines. METHODS: In this open-label, randomised, controlled study, eligible healthy infants 6-12 weeks of age recruited through five clinical trials units (four in the UK and one in Malta) were randomly assigned in a 1:1 ratio to two vaccination groups: consistent limb or alternating limb. …”

Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial. by Hamaluba, M, Kandasamy, R, Upreti, S, Subedi, G, Shrestha, S, Bhattarai, S, Gurung, M, Pradhan, R, Voysey, M, Gurung, S, Pradhan, S, Thapa, A, Maharjan, R, Kiran, U, Kerridge, S, Hinds, J, van der Klis, F, Snape, M, Murdoch, D, Kelly, S, Kelly, D, Adhikari, N, Thorson, S, Pollard, A

“…BACKGROUND: Use of pneumococcal conjugate vaccines (PCVs) in resource-poor countries has focused on early infant immunisation with little emphasis on protection in late infancy and beyond. …”

Prevalence and decay of maternal pneumococcal and meningococcal antibodies: a meta-analysis of type-specific decay rates by Voysey, M, Pollard, A, Sadarangani, M, Fanshawe, T

“… <p><b>Background:</b> At the time of an infant’s initial vaccination at age ∼2 to 3 months, some infants already have maternal antibodies against vaccine antigens and these can suppress the immune response to vaccination. …”

Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children: study protocol for an individual par... by Voysey, M, Pollard, A, Perera, R, Fanshawe, T

“…Factors other than sex, such as timing or co-administration of other vaccines, can also influence an infant’s immune response to vaccination. <strong>Methods and Analysis:</strong> Individual participant data meta-analysis of randomised controlled trials of vaccines in healthy infants and young children will be conducted. …”

Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries by Voysey, M, Fanshawe, T, Kelly, D, O'Brien, K, Kandasamy, R, Shrestha, S, Thorson, S, Hinds, J, Pollard, A

“…Pneumococcal conjugate vaccines (PCVs) provide direct protection against disease in those vaccinated, and interrupt transmission through the prevention of nasopharyngeal carriage.We analysed immunogenicity data from 5224 infants who received PCV in prime-boost schedules. …”